Seller record · Telehealth service

MEDvidi

Fails 3 of 8 criteria. S3, pharmacy identification: No filling pharmacy is named. The terms say the company is not a pharmacy, prescriptions are sent to the patient's pharmacy, and the refund policy says it does not control pharmacy operations. 2 more criteria also fail; see the table below.

At a glance

MEDvidiTelehealth service

5/8criteria passed
Price
Not printed before a consultation or sign-up
Sells
Wegovy, Ozempic, Rybelsus, and 7 more
FDA letters
None on file
Visit MEDvidiSee all eight dispositions

Telehealth service. Passes 5 of 8 criteria. Recorded against Standard v1.1.

An online mental health practice whose licensed providers also prescribe brand-name GLP-1 medications such as Wegovy, Ozempic, Zepbound and Mounjaro, along with other weight loss drugs, through paid video appointments, with prescriptions sent to the patient's pharmacy.

Operating entity MEDvidi Inc.

Dispositions

CodeCriterionDispositionWhere it appears
S1Prescriber requirementPASSMEDvidi's weight loss treatment page; MEDvidi's terms and conditions
S2Prescription gatingPASSMEDvidi's FAQ; MEDvidi's payment terms
S3Pharmacy identificationFAILMEDvidi's terms and conditions; MEDvidi's refund policy
S4Compounding disclosurePASSMEDvidi's weight loss treatment page
S5Analytical documentationFAILMEDvidi's weight loss treatment page; MEDvidi's FAQ; MEDvidi's terms and conditions
S6Business addressPASSMEDvidi's contact page; MEDvidi's terms of use page
S7Price disclosureFAILMEDvidi's weight loss treatment page; MEDvidi's FAQ
S8Enforcement statusPASSFDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSA licensed provider assesses each patient's physical and emotional state in a video visit and prescribes weight loss medication only if appropriate, and the terms say clinical care is given through MEDVidi Health P.C., a California professional corporation, through its medical director.Source: MEDvidi's weight loss treatment page; MEDvidi's terms and conditions.
S2PASSThe answers list creating an account and filling out the intake form first, then reserving and paying for an appointment, and the video visit with a provider is the evaluation.Source: MEDvidi's FAQ; MEDvidi's payment terms.
S3FAILNo filling pharmacy is named. The terms say the company is not a pharmacy, prescriptions are sent to the patient's pharmacy, and the refund policy says it does not control pharmacy operations.Source: MEDvidi's terms and conditions; MEDvidi's refund policy.
S4PASSThe weight loss page lists brand-name medications, including Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound and Saxenda, by their active ingredients, and the word compounded appears on none of its pages.Source: MEDvidi's weight loss treatment page.
S5FAILNo certificate of analysis or lot document is published on the weight loss page, the answers or the terms.Source: MEDvidi's weight loss treatment page; MEDvidi's FAQ; MEDvidi's terms and conditions.
S6PASSMEDvidi Inc. at 4010 Moorpark Ave., Suite 114, San Jose, CA 95117, printed on the contact page and as the mailing address in the terms. The terms name California law.Source: MEDvidi's contact page; MEDvidi's terms of use page.
S7FAILNo GLP-1 medication price is printed. An introductory weight loss consultation costs $195, a package with one follow-up $249 and a follow-up consultation $159, and the answers say the patient pays only for the appointment.Source: MEDvidi's weight loss treatment page; MEDvidi's FAQ.
S8PASSNo FDA warning letter names MEDvidi, MEDvidi Inc. or MEDVidi Health P.C., and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: Wegovy, Ozempic, Rybelsus, Zepbound, Mounjaro, Saxenda, Trulicity, phentermine, Qsymia, Contrave.

Visit MEDvidi

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.